Omixon’s OmniType is Now Available Under Early Access

BUDAPEST, Hungary and CAMBRIDGE, Mass. (PRWEB) February 03, 2020 Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is available through an Early Access…

Source link

Related posts

H2Bub1 Regulates RbohD-Dependent Hydrogen Peroxide Signal Pathway in the Defense Responses to Verticillium dahliae Toxins


Trans-scale mechanotransductive cascade of biochemical and biomechanical patterning in embryonic development: the light side of the force.


A novel nonosteocytic regulatory mechanism of bone modeling


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy